Lynk Pharmaceuticals
PrivateLast Round
Series C
Extension
May 31, 2023
Total Funding Raised
$28.25M
Company Overview
Lynk Pharmaceuticals is a clinical-stage pharmaceutical company that develops small molecule drugs intended to treat tumors and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lynk Pharmaceuticals Comps
Public and private peers based on sector, stage, and business model.
Lynk Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | May 31, 2023 |
Key People
Founding team and executive leadership
Lynk Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Tailong Investment | Series C Extension |
| Liando Investment | Series C Extension |
| Shengshi Capital | Series C Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 1, 2025
Preparing for NDA submission and international audits.
Lynk Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Lynk Pharmaceuticals's valuation, stock price, and market status.
